N-Myc Downstream-Regulated Gene 4 (NDRG4): A Candidate Tumor Suppressor Gene and Potential Biomarker for Colorectal Cancer

Journal of the National Cancer Institute

Volumn 101, Issue 13, 2009, Pages 916-927

  Melotte, Veerle ^a   Lentjes, Marjolein H F M ^a   Van Den Bosch, Sandra M ^a   Hellebrekers, Debby M E I ^a   De Hoon, Joep P J ^a   Wouters, Kim A D ^a   Daenen, Kathleen L J ^a   Partouns Hendriks, Iris E J M ^a   Stessels, Filip ^a   Louwagie, Joost ^b   Smits, Kim M ^a   Weijenberg, Matty P ^a   Sanduleanu, Silvia ^a   Khalid De Bakker, Carolina A J ^a   Oort, Frank A ^c   Meijer, Gerrit A ^c   Jonkers, Daisy M A E ^a   Herman, James G ^d   De Bruïne, Adriaan P ^a   Van Engeland, Manon ^a,e  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b OncoMethylome Sciences SA   (Belgium)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; BISULFITE; DNA; MESSENGER RNA; TUMOR SUPPRESSOR PROTEIN; MUSCLE PROTEIN; NDRG4 PROTEIN, HUMAN; NERVE PROTEIN; TUMOR MARKER;

ARTICLE; CANCER CELL CULTURE; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; COLON; COLON MUCOSA; COLONY FORMATION; COLORECTAL CANCER; CONTROLLED STUDY; FECES; GENE OVEREXPRESSION; GENE SEQUENCE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; N MYC DOWNSTREAM REGULATED GENE 4; NUCLEOTIDE SEQUENCE; ONCOGENE C MYB; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN METHYLATION; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TUMOR SUPPRESSOR GENE; ADENOMA; ADULT; AGED; CANCER DIAGNOSIS; CANCER INVASION; CARCINOMA; CASE CONTROL STUDY; CELL MOTION; CHEMISTRY; COLORECTAL TUMOR; DNA METHYLATION; DRUG SCREENING; FEMALE; GENE EXPRESSION REGULATION; GENETICS; INTESTINE MUCOSA; MALE; MIDDLE AGED; RETROSPECTIVE STUDY; UPREGULATION;

ADENOMA; ADULT; AGED; CARCINOMA; CASE-CONTROL STUDIES; CELL MOVEMENT; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DNA METHYLATION; EARLY DETECTION OF CANCER; FECES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; IMMUNOHISTOCHEMISTRY; INTESTINAL MUCOSA; MALE; MIDDLE AGED; MUSCLE PROTEINS; NEOPLASM INVASIVENESS; NERVE TISSUE PROTEINS; POLYMERASE CHAIN REACTION; PREVALENCE; PROMOTER REGIONS, GENETIC; RETROSPECTIVE STUDIES; RNA, MESSENGER; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; TUMOR STEM CELL ASSAY; UP-REGULATION;

EID: 67649635452     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djp131     Document Type: Article

References (51)

1. Hellebrekers DM, Melotte V, Vire E, et al. Identification of epigenetically silenced genes in tumor endothelial cells. Cancer Res. 2007;67(9): 4138-4148.
2. Zhou RH, Kokame K, Tsukamoto Y, et al. Characterization of the human NDRG gene family: a newly identified member, NDRG4, is specifically expressed in brain and heart. Genomics. 2001;73(1):86-97.
3. Qu X, Zhai Y, Wei H, et al. Characterization and expression of three novel differentiation-related genes belong to the human NDRG gene family. Mol Cell Biochem. 2002;229(1-2):35-44.
4. Bandyopadhyay S, Pai SK, Gross SC, et al. The Drg-1 gene suppresses tumor metastasis in prostate cancer. Cancer Res. 2003;63(8):1731-1736.
5. Bandyopadhyay S, Pai SK, Hirota S, et al. Role of the putative tumor metastasis suppressor gene Drg-1 in breast cancer progression. Oncogene. 2004;23(33):5675-5681.
6. Guan RJ, Ford HL, Fu Y, et al. Drg-1 as a differentiation-related, putative metastatic suppressor gene in human colon cancer. Cancer Res. 2000;60(3):749-755.
7. van Belzen N, Dinjens WN, Diesveld MP, et al. A novel gene which is up-regulated during colon epithelial cell differentiation and down- regulated in colorectal neoplasms. Lab Invest. 1997;77(1):85-92.
8. Kurdistani SK, Arizti P, Reimer CL, et al. Inhibition of tumor cell growth by RTP/rit42 and its responsiveness to p53 and DNA damage. Cancer Res. 1998;58(19):4439-4444.
9. Shah MA, Kemeny N, Hummer A, et al. Drg1 expression in 131 colorectal liver metastases: correlation with clinical variables and patient outcomes. Clin Cancer Res. 2005;11(9):3296-3302.
10. Lusis EA, Watson MA, Chicoine MR, et al. Integrative genomic analysis identifies NDRG2 as a candidate tumor suppressor gene frequently inactivated in clinically aggressive meningioma. Cancer Res. 2005;65(16): 7121-7126.
11. Deng Y, Yao L, Chau L, et al. N-Myc downstream-regulated gene 2 (NDRG2) inhibits glioblastoma cell proliferation. Int J Cancer. 2003; 106(3):342-347.
12. Liu N, Wang L, Liu X, et al. Promoter methylation, mutation, and genomic deletion are involved in the decreased NDRG2 expression levels in several cancer cell lines. Biochem Biophys Res Commun. 2007;358(1):164-169.
13. Nakada N, Hongo S, Ohki T, Maeda A, Takeda M. Molecular characterization of NDRG4/Bdm1 protein isoforms that are differentially regulated during rat brain development. Brain Res Dev Brain Res. 2002; 135(1-2):45-53.
14. Ohki T, Hongo S, Nakada N, Maeda A, Takeda M. Inhibition of neurite outgrowth by reduced level of NDRG4 protein in antisense transfected PC12 cells. Brain Res Dev Brain Res. 2002;135(1-2):55-63.
15. Maeda A, Hongo S, Miyazaki A. Genomic organization, expression, and comparative analysis of noncoding region of the rat Ndrg4 gene. Gene. 2004;324:149-158.
16. Hongo S, Watanabe T, Takahashi K, Miyazaki A. Ndrg4 enhances NGF- induced ERK activation uncoupled with Elk-1 activation. J Cell Biochem. 2006;98(1):185-193.
17. van den Brandt PA, Goldbohm RA, van 't Veer P, et al. A large-scale prospective cohort study on diet and cancer in the Netherlands. J Clin Epidemiol. 1990;43(3):285-295.
18. Brink M, de Goeij AF, Weijenberg MP, et al. K-ras oncogene mutations in sporadic colorectal cancer in the Netherlands Cohort Study. Carcinogenesis. 2003;24(4):703-710.
19. Hermanek P, Scheibe O, Spiessl B, Wagner G. [TNM classification of malignant tumors: the new 1987 edition]. Rontgenblatter. 1987;40(6):200.
20. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation- specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA. 1996;93(18):9821-9826.
21. van Engeland M, Weijenberg MP, Roemen GM, et al. Effects of dietary folate and alcohol intake on promoter methylation in sporadic colorectal cancer: the Netherlands Cohort Study on Diet and Cancer. Cancer Res. 2003;63(12):3 133-3137.
22. Thijssen VL, Brandwijk RJ, Dings RP, Griffioen AW. Angiogenesis gene expression profiling in xenograft models to study cellular interactions. Exp Cell Res. 2004;299(2):286-293.
23. Janes H, Pepe MS. Adjusting for covariates in studies of diagnostic, screening, or prognostic markers: an old concept in a new setting. Am J Epidemiol. 2008;168(1):89-97.
24. Issa JP, Ahuja N, Toyota M, Bronner MP, Brentnall TA. Accelerated age- related CpG island methylation in ulcerative colitis. Cancer Res. 2001; 61(9):3573-3577.
25. Weisenberger DJ, Siegmund KD, Campan M, et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet. 2006;38(7):787-793.
26. Derks S, Postma C, Carvalho B, et al. Integrated analysis of chromosomal, microsatellite and epigenetic instability in colorectal cancer identifies specific associations between promoter methylation of pivotal tumour suppressor and DNA repair genes and specific chromosomal alterations. Carcinogenesis. 2008;29(2):43 4-439.
27. Turker MS. Gene silencing in mammalian cells and the spread of DNA methylation. Oncogene. 2002;21(35):5388-5393.
28. Homma N, Tamura G, Honda T, et al. Spreading of methylation within RUNX3 CpG island in gastric cancer. Cancer Sci. 2006;97(1):51-56.
29. Sjoblom T, Jones S, Wood LD, et al. The consensus coding sequences of human breast and colorectal cancers. Science. 2006;314(5797):268-274.
30. Rakha EA, Green AR, Powe DG, Roylance R, Ellis IO. Chromosome 16 tumor-suppressor genes in breast cancer. Genes Chromosomes Cancer. 2006;45(6):527-535.
31. Bando K, Nagai H, Matsumoto S, et al. Identification of a 1-Mb common region at 16q24.1-24.2 deleted in hepatocellular carcinoma. Genes Chromosomes Cancer. 2000;28(1):38-44.
32. Sakai K, Nagahara H, Abe K, Obata H. Loss of heterozygosity on chromosome 16 in hepatocellular carcinoma. J Gastroenterol Hepatol. 1992; 7(3):288-292.
33. Elo JP, Harkonen P, Kyllonen AP, et al. Loss of heterozygosity at 16q24.1-q24.2 is significantly associated with metastatic and aggressive behavior of prostate cancer. Cancer Res. 1997;57(16):3356-3359.
34. Kawakami M, Staub J, Cliby W, et al. Involvement of H-cadherin (CDH13) on 16q in the region of frequent deletion in ovarian cancer. Int J Oncol. 1999;15(4):715-720.
35. Mason JE, Goodfellow PJ, Grundy PE, Skinner MA. 16q Loss of heterozygosity and microsatellite instability in Wilms' tumor. J Pediatr Surg. 2000;35(6):891-896; discussion 896-897.
36. Zou H, Harrington J, Rego RL, Ahlquist DA. A novel method to capture methylated human DNA from stool: implications for colorectal cancer screening. Clin Chem. 2007;53(9):1646-1651.
37. Chen WD, Han ZJ, Skoletsky J, et al. Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene. J Natl Cancer Inst. 2005;97(15):1124-1132.
38. Muller HM, Oberwalder M, Fiegl H, et al. Methylation changes in faecal DNA:a marker for colorectal cancer screening? Lancet. 2004;363(9417):1283-1285.
39. Lenhard K, Bommer GT, Asutay S, et al. Analysis of promoter methyla- tion in stool: a novel method for the detection of colorectal cancer. Clin Gastroenterol Hepatol. 2005;3(2):142-149.
40. Leung WK, To KF, Man EP, et al. Detection of epigenetic changes in fecal DNA as a molecular screening test for colorectal cancer: a feasibility study. Clin Chem. 2004;50(11):2179-2182.
41. Belshaw NJ, Elliott GO, Williams EA, et al. Use of DNA from human stools to detect aberrant CpG island methylation of genes implicated in colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2004;13(9): 1495-1501.
42. Petko Z, Ghiassi M, Shuber A, et al. Aberrantly methylated CDKN2A, MGMT, and MLH1 in colon polyps and in fecal DNA from patients with colorectal polyps. Clin Cancer Res. 2005;11(3):1203-1209.
43. Ahlquist DA, Sargent DJ, Loprinzi CL, et al. Stool DNA and occult blood testing for screen detection of colorectal neoplasia. Ann Intern Med. 2008;149(7):441-450W81.
44. Ebert MP, Model F, Mooney S, et al. Aristaless-like homeobox-4 gene methylation is a potential marker for colorectal adenocarcinomas. Gastroenterology. 2006;131(5):1418-1430.
45. Grady WM, Rajput A, Lutterbaugh J D, Markowitz SD. Detection of aberrantly methylated hMLH1 promoter DNA in the serum of patients with microsatellite unstable colon cancer.Cancer Res. 2001;61(3):900-902.
46. Leung WK, To KF, Man EP, et al. Quantitative detection of promoter hypermethylation in multiple genes in the serum of patients with colorectal cancer. Am J Gastroenterol. 2005;100(10):2274-2279.
47. Han M, Liew CT, Zhang HW, et al. Novel blood-based, five-gene biomarker set for the detection of colorectal cancer. Clin Cancer Res. 2008;14(2):455-460.
48. Zou HZ, Yu BM, Wang ZW, et al. Detection of aberrant p16 methylation in the serum of colorectal cancer patients. Clin Cancer Res. 2002; 8(1):188-191.
49. Frattini M, Gallino G, Signoroni S, et al. Quantitative analysis of plasma DNA in colorectal cancer patients: a novel prognostic tool. Ann N YAcad Sci. 2006;1075:185-190.
50. Itzkowitz S, Brand R, Jandorf L, et al. A simplified, noninvasive stool DNA test for colorectal cancer detection. Am J Gastroenterol. 2008; 103(11):2862-2870.
51. Itzkowitz SH, Jandorf L, Brand R, et al. Improved fecal DNA test for col- orectal cancer screening. Clin Gastroenterol Hepatol. 2007;5(1):111-117.